Synthesis method of free racemization salbutamol
By adopting a combination of benzyl protection reaction, epoxidation reaction, addition reaction and hydrogenation reaction, the problems of low reaction yield and difficult separation of impurities in the existing albuterol synthesis methods are solved, and efficient and simple albuterol synthesis is achieved. Suitable for industrial production.
Patent Information
- Application Number
- CN202411137087.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-26
AI Technical Summary
There are many shortcomings in the existing synthesis method of albuterol, including low reaction yield, difficult separation of impurities, many side reactions, harsh reaction conditions, safety hazards, and high costs, which are difficult to be suitable for industrial production.
The combination of benzyl protection reaction, epoxidation reaction, addition reaction and hydrogenation reaction is adopted to synthesize albuterol by selective protection against phenolic hydroxyl monobenzyl, avoiding the use of high-risk and highly toxic agents, and the reaction conditions are mild , low equipment requirements, simple operation, suitable for industrial production.
It achieves a high yield, high purity, easy separation and simple operation of albuterol synthesis, avoids side reactions and high costs, and is suitable for industrial production.
Smart Images

Figure CN119019271A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical chemistry, and particularly relates to a method for synthesizing free racemic salbutamol. Background Art
[0002] Salbutamol, trade name: salbutamol, is a β2-receptor agonist with strong and slow effects. It was discovered by British scholars in 1962, developed by Glaxo, first marketed in 1968, registered in my country in 1988, and produced in China in 1975. Although it is an old drug, it still plays an irreplaceable role. In recent years, its sales in the world pharmaceutical market have ranked among the top 20.
[0003] As a selective β2-receptor agonist, salbutamol can effectively inhibit the release of allergenic substances such as histamine and prevent bronchospasm. It is suitable for bronchial asthma, asthmatic bronchitis, bronchospasm, emphysema and other diseases. It is absorbed slowly in the trachea and is not easily destroyed by sulfatase in the body, so its effect is strong and lasting. In addition, salbutamol has a weak stimulating effect on the β1-receptors of the heart, so its effect of increasing heart rate is only 1 / 10 of that of isoproterenol. With the high incidence of respiratory diseases, the amount of salbutamol will remain high. Although there are many methods for synthesizing salbutamol, most of the routes are difficult to apply to industrial production, or there are problems such as low total yield, high production and environmental treatment costs.
[0004] At present, there are mainly five methods for synthesizing racemic salbutamol:
[0005] 1. The reaction route reported by Babd Esther in Synthes is in 1988 is as follows:
[0006]
[0007] However, this route has the following disadvantages: (1) the Friedel-Crafts acylation reaction will generate other positional isomers, resulting in a decrease in reaction yield and difficulty in separating impurities; (2) the imine generated by the reaction is unstable, making the reaction process uncontrollable and the purity reduced.
[0008] 2. The early domestic production and synthesis technology routes are as follows:
[0009]
[0010] This route has the following disadvantages: (1) the route is long, there are many side reactions, and it is difficult to separate impurities; (2) the two hydroboration reductions require very high reaction control and are difficult to handle industrially.
[0011] 3. Francisco Ayala-Mata reported the following synthetic route in Molecules in 2012:
[0012]
[0013] This synthesis method involves reactions such as lithium aluminum hydride reduction and n-butyl lithium bromination, which have stringent requirements on reaction conditions and pose safety risks, making it unsuitable as a reaction route for industrial production.
[0014] 4. Yang Qiaoming reported the following synthetic route in his 2015 patent:
[0015]
[0016] In the whole route, the raw materials are cheap and easy to obtain, and the operation is simple, which greatly reduces the production cost. However, there are still the following problems: the intermediate product of propylidene protection is an oily substance, the impurities of aldol condensation are difficult to remove; when the epoxide and tert-butylamine undergo addition reaction, the isomer impurities generated are not easy to separate and purify.
[0017] 5. The synthesis route reported in the 2021 patent CN11259228 is as follows:
[0018]
[0019] The third step, the Suzuki Miyaura cross-coupling reaction, is demanding. The potassium triethylene fluoroborate and palladium chloride used are expensive, and the precious metal palladium is used later, which makes the reaction cost high. In the last step, during the hydrogenation debenzylation, the selectivity of the benzyl group on the methoxy group is poor, which easily produces by-products, resulting in more impurities and reduced yield.
[0020] There are many methods for synthesizing salbutamol, but most of them have many shortcomings. Therefore, it is necessary to further develop a more reasonable method for synthesizing salbutamol. Summary of the invention
[0021] The object of the present invention is to provide a method for synthesizing free racemic salbutamol to solve the problems mentioned above.
[0022] To achieve the above object, the present invention provides the following technical solutions:
[0023] A method for synthesizing free racemic salbutamol,
[0024] The following steps are involved:
[0025]
[0026] S1, benzyl protection reaction: raw material 1 reacts with benzyl bromide and potassium carbonate under heating conditions to generate intermediate 2;
[0027] S2, epoxidation reaction: Intermediate 2 reacts with trimethylsulfonium bromide under strong alkaline conditions to generate intermediate 3;
[0028] S3, addition reaction: intermediate 3 reacts with tert-butylamine under heating conditions to generate intermediate 4;
[0029] S4, hydrogenation reaction: intermediate 4 reacts with hydrogen under palladium-carbon catalysis to obtain salbutamol 5.
[0030] Preferably, in S1, raw material 1, benzyl bromide and potassium carbonate are mixed, a solvent is added, the temperature is raised to 30-60° C., and the temperature is kept for reaction for 3-10 hours to obtain intermediate 2;
[0031] In S2, intermediate 2 and trimethylsulfonium bromide are dissolved in an organic solvent, the temperature is controlled to 10-30°C, and then a strong base is added. The reaction time is 1-4 hours to obtain intermediate 3;
[0032] In S3, the intermediate 3 is dissolved in an organic solvent, an induction catalyst (TiO2 mesoporous molecular sieve) and tert-butylamine are added, the temperature is raised to 60-100°C, and the reaction is carried out for 12-48 hours to obtain the intermediate 4;
[0033] In S4, the intermediate 4 is dissolved in an organic solvent, palladium carbon is added, hydrogen is introduced, and the reaction is carried out at 20-60° C. for 4-20 hours to obtain salbutamol 5.
[0034] Preferably, the molar ratio of the raw material 1, benzyl bromide and potassium carbonate in S1 is 1:(1.1-1.5):(1.1-1.5), the benzylating agent is selected from benzyl bromide or benzyl chloride, and the organic solvent is selected from acetonitrile, DMF, DMSO, acetone and tetrahydrofuran.
[0035] Preferably, in S2, the molar ratio of intermediate 2, strong base and trimethylsulfonium bromide is 1:(1.0-1.5):(1.2-1.5), the organic solvent is selected from one of DMF, tert-butanol, DMSO and tetrahydrofuran or a mixed solvent, the strong base is selected from sodium hydride or potassium tert-butoxide, and the sulfonium salt is any one of trimethylsulfonium bromide and trimethylsulfoxide bromide.
[0036] Preferably, in S3, the molar ratio of intermediate 3 to tert-butylamine is 1:(6-10), the solvent is one of acetonitrile, 1,4-dioxane and tert-butylamine, and the catalyst is TiO2 mesoporous molecular sieve, and the addition amount thereof is 0-10%.
[0037] Preferably, in S4, the molar ratio of intermediate 4 to palladium carbon is 1:(0.05-0.01), the hydrogen pressure is 0.1-0.5 MPa, and the organic solvent can be selected from one of acetonitrile, methanol, ethanol, and THF.
[0038] Compared with the prior art, the present invention has the following beneficial effects:
[0039] The synthetic route of the invention uses 4-hydroxy-3-hydroxymethylbenzaldehyde as a raw material, and for the first time adopts a method of selectively protecting the monobenzyl group of the phenolic hydroxyl group to synthesize salbutamol; the monobenzyl protection has good selectivity, high yield, and convenient benzyl removal without side reactions; the intermediates protected by the monobenzyl group are mostly solid, easy to recrystallize, and convenient to separate and purify; the use of high-risk and highly toxic reagents is avoided, the reaction conditions are mild, the equipment requirements are low, the operation is simple, the controllability is strong, the post-treatment is simple, and the product is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 For intermediate 2 1 H NMR spectra;
[0041] Figure 2 For intermediate 3 1 H NMR spectra;
[0042] Figure 3 For intermediate 4 1 H NMR spectra;
[0043] Figure 4 For salbutamol 5 1 H NMR spectra;
[0044] Figure 5 This is the HPLC chart of salbutamol 5. DETAILED DESCRIPTION
[0045] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0046] Embodiment 1:
[0047] Preparation of Intermediate 2:
[0048] Add 300 mL of acetone and 37.1 g of benzyl bromide to a 500 mL three-necked flask, add 30.0 g of raw material 1 and 35.4 g of anhydrous potassium carbonate under stirring, heat to reflux, keep warm for 8 hours, and stop the reaction when the reaction is complete by TLC detection. Cool to room temperature, filter, and concentrate the filtrate to dryness to obtain a light yellow solid. Pulp with toluene to obtain 47.6 g of white solid 2, with a yield of 98%. Intermediate 2 1 HNMR Figure 1 As shown, 1 H NMR (400MHz, CDCl3) δ: 9.89 (s, 1H), 7.91 (s, 1H), 7.80 (d, J = 8.4Hz, 1H), 7.35 ~7.41(m,5H),7.05(d,J=8.4Hz,1H),5.20(s,2H),4.78(s,2H),2.24(s,1H).
[0049] Preparation of intermediate 3:
[0050] At 20°C, add 180mL of dimethyl sulfoxide, 17.3g of trimethylsulfonium bromide, 19.1g of intermediate 2 and 10.6g of potassium tert-butoxide to a 500mL three-necked flask, keep warm for 1h, and stop the reaction when the reaction is complete after TLC detection. Add 100mL of dichloromethane to the reaction solution, stir well and filter, add the filtrate to 2L of water, stir well, stand and separate to obtain the organic phase. Wash the organic phase with 2L of water for 2 times, dry with anhydrous sodium sulfate, and concentrate under reduced pressure at 25°C to obtain 20.2g of light yellow oil 3, with a yield of 99%. Intermediate 3 1 H NMR Figure 2 As shown, 1 H NMR (400MHz, CDCl3) δ: 7.21~7.31 (m, 6H), 7.02 (dd, J = 8.4Hz, 1H), 6.76 (d, J = 8.4Hz, 1H), 4.92 (s, 2H) ,4.62(s,2H),3.65(dd,J=4.1,2.7Hz,1H),2.93(dd,J=5.3,4.1Hz,1H),2.66(dd,J=5.3,2.7Hz,1H).
[0051] Preparation of intermediate 4:
[0052] 43 mL of tert-butylamine and 10.0 g of intermediate 3 were added to a 100 mL jar, and the temperature was raised to 100 °C under closed stirring conditions. The reaction was kept warm for 24 hours and the reaction was stopped. The reaction solution was concentrated to dryness under reduced pressure and then recrystallized from ethyl acetate to obtain 9.7 g of white solid 4 with a yield of 75%. 1 H NMR Figure 3 As shown, 1H NMR (400MHz, DMSO-d6) δ: 7.50~7.26 (m, 6H), 7.15 (d, J = 8.4Hz, 1H), 6.95 (d, J = 8.4Hz, 1H), 5.11(s,2H),4.96(s,1H),4.56(s,2H),4.53~4.42(m,1H),2.69~2.54(m,2H),1.04(s,9H).
[0053] Preparation of salbutamol 5:
[0054] 5.0 g of intermediate 4 was placed in a high pressure reactor, 60 mL of methanol was added and stirred to dissolve, then 0.25 g of 5% palladium on carbon was added, hydrogen (pressure 0.20 MPa) was introduced, and the hydrogenation reaction was carried out at room temperature overnight. The sample was taken for TLC analysis, and the reaction of the raw material was complete. The reaction was stopped, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent to obtain 4.0 g of crude product. The crude product was slurried with a mixed solvent of ethyl acetate and ethanol to obtain 3.5 g of white solid 5, with a yield of 95%. Salbutamol 5 1 H NMR Figure 4 As shown, 1 H NMR (400MHz, DMSO-d6) δ: 7.26 (d, J=2.0Hz, 1H), 6.99 (dd, J=8.2, 2.0Hz, 1H), 6.6 9(d,J=8.2Hz,1H),4.46(s,2H),4.39(t,J=6.3Hz,1H),2.53(m,2H),1.01(s,9H).
[0055] Embodiment 2
[0056] Preparation of Intermediate 2:
[0057] To a 500mL three-necked flask, add 300mL acetone and 27.8g benzyl chloride, add 30.0g raw material 1 and 35.4g anhydrous potassium carbonate under stirring, heat to reflux, keep warm for 8h, and when the reaction is complete, stop the reaction, cool to room temperature, filter, and concentrate the filtrate to dryness to obtain a light yellow solid. Slurry with toluene to obtain 45.7g white solid 2, with a yield of 98%.
[0058] Preparation of intermediate 3:
[0059] At 30°C, add 180 mL of dimethyl sulfoxide, 19.0 g of trimethyl sulfoxide bromide, 19.1 g of intermediate 2 and 10.6 g of potassium tert-butoxide to a 500 mL three-necked flask, keep warm for 4 hours, and stop the reaction when the reaction is complete by TLC detection. Add 100 mL of dichloromethane to the reaction solution, stir well and filter, add the filtrate to 2 L of water, stir well, stand and separate to obtain an organic phase. Add the organic phase to 2 L of water and repeat the above operation twice, dry the organic phase with anhydrous sodium sulfate, and concentrate under reduced pressure at 25°C to obtain 19.6 g of light yellow oil 3, with a yield of 99%.
[0060] Preparation of intermediate 4:
[0061] In a 100 mL stuffing pot, 43 mL of tert-butylamine, 10.0 g of intermediate 3 and 0.1 g of TiO2 mesoporous molecular sieve were added. The temperature was raised to 60°C under closed stirring conditions. The reaction was kept warm for 24 h and the reaction was stopped. The reaction solution was concentrated to dryness under reduced pressure and then recrystallized from ethyl acetate to obtain 10.3 g of white solid 4 with a yield of 80%.
[0062] Preparation of salbutamol 5:
[0063] 5.0 g of intermediate 4 was placed in an autoclave, 60 mL of ethanol was added and stirred to dissolve, and then 0.25 g of 5% palladium on carbon was added, and hydrogen (pressure 0.20 MPa) was introduced. The hydrogenation reaction was carried out at room temperature overnight, and the sample was taken for TLC analysis. The raw material reaction was completed. The reaction was stopped, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent to obtain 4.0 g of crude product. The crude product was slurried with a mixed solvent of ethyl acetate and ethanol to obtain 3.5 g of white solid 5, with a yield of 95%.
[0064] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "examples", "specific examples" or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification and the features of different embodiments or examples, unless they are contradictory.
[0065] In the drawings of the embodiments disclosed in the present invention, only the structures related to the embodiments disclosed in the present invention are involved, and other structures can refer to the general design. In the absence of conflict, the same embodiment and different embodiments of the present invention can be combined with each other.
[0066] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for synthesizing free racemic salbutamol, characterized in that: The following steps are involved: S1, benzyl protection reaction: raw material 1 reacts with benzyl bromide and potassium carbonate under heating conditions to generate intermediate 2; S2, epoxidation reaction: Intermediate 2 reacts with trimethylsulfonium bromide under strong alkaline conditions to generate intermediate 3; S3, addition reaction: intermediate 3 reacts with tert-butylamine under heating conditions to generate intermediate 4; S4, hydrogenation reaction: intermediate 4 reacts with hydrogen under palladium-carbon catalysis to obtain salbutamol 5.
2. A method for synthesizing free racemic salbutamol according to claim 1, characterized in that: In S1, raw material 1, benzyl bromide and potassium carbonate are mixed, a solvent is added, the temperature is raised to 30-60° C., and the temperature is kept for reaction for 3-10 hours to obtain intermediate 2; In S2, intermediate 2 and trimethylsulfonium bromide are dissolved in an organic solvent, the temperature is controlled to 10-30°C, and then a strong base is added. The reaction time is 1-4 hours to obtain intermediate 3; In S3, the intermediate 3 is dissolved in an organic solvent, an induction catalyst (TiO2 mesoporous molecular sieve) and tert-butylamine are added, the temperature is raised to 60-100° C., and the reaction is carried out for 12-48 hours to obtain the intermediate 4; In S4, the intermediate 4 is dissolved in an organic solvent, palladium carbon is added, hydrogen is introduced, and the reaction is carried out at 20-60° C. for 4-20 hours to obtain salbutamol 5.
3. A method for synthesizing free racemic salbutamol according to claim 1, characterized in that: The molar ratio of the raw material 1, benzyl bromide and potassium carbonate in S1 is 1:(1.1-1.5):(1.1-1.5), the benzylating agent is selected from benzyl bromide or benzyl chloride, and the organic solvent is selected from acetonitrile, DMF, DMSO, acetone and tetrahydrofuran.
4. A method for synthesizing free racemic salbutamol according to claim 1, characterized in that: In S2, the molar ratio of intermediate 2, strong base and trimethylsulfonium bromide is 1:(1.0-1.5):(1.2-1.5), the organic solvent is selected from one of DMF, tert-butanol, DMSO and tetrahydrofuran or a mixed solvent, the strong base is selected from sodium hydride or potassium tert-butoxide, and the sulfonium salt is any one of trimethylsulfonium bromide and trimethylsulfoxide bromide.
5. A method for synthesizing free racemic salbutamol according to claim 1, characterized in that: In S3, the molar ratio of intermediate 3 to tert-butylamine is 1:(6-10), the solvent is one of acetonitrile, 1,4-dioxane and tert-butylamine, and the catalyst is TiO2 mesoporous molecular sieve, and the addition amount thereof is 0-10%.
6. The method for synthesizing racemic salbutamol according to claim 1, characterized in that: In S4, the molar ratio of intermediate 4 to palladium carbon is 1:(0.05-0.01), the hydrogen pressure is 0.1-0.5 MPa, and the organic solvent can be selected from acetonitrile, methanol, ethanol, and THF.
